drugset / Trial / NCT04526990

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

NCT04526990

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above.

Timeline

Start
2020-09-15
Primary completion
2021-08-07
Completion
2022-10-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad5-nCoV Vaccine 0.5 ml Intramuscular

Indications